The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 4 Stan Schwartz MD, FACP, FACE.

Slides:



Advertisements
Similar presentations
What Causes Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes? Charles A. Reasner, MD Professor of Medicine University of.
Advertisements

Clinical Presentation of Type 2 Diabetes 1. Risk Factors for Prediabetes and Type 2 Diabetes Family history of diabetes mellitus Cardiovascular disease.
Type 2 diabetes Years from diagnosis Pre-diabetes Onset Diagnosis Insulin secretion Insulin “efficiency” Ramlo-Halsted BA, Edelman SV.
DM Dewasa EVA DECROLI. Problems Increased of prevalence Cronic complications ex. Diabetic Foot Problems Prevention, primer, secunder tertier.
Islets of Langerhan. Prof. K. Sivapalan Islets of Langerhan2 Histology. A cells 20 % [glucogon] B cells 50% [Insulin] D cells 8% [somatostatin]
Dr Hassan Makki DO FACC Phoenix Heart Center.  Diabetes mellitus (DM) is a group of diseases characterized by high levels of blood glucose resulting.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
MSc in Diabetes A population approach Ross Lawrenson Postgraduate Medical School University of Surrey Impaired glucose tolerance and undiagnosed diabetes.
Therapy of Type 2 Diabetes Mellitus: UPDATE
METABOLIC Syndrome: a Global Perspective
Epidemiology of Diabetes Mellitus by Santi Martini Departemen of Epidemiology Faculty of Public Health University of Airlangga.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stanley Schwartz.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 1 of 5.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 3 Stan Schwartz MD, FACP, FACE.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
TYPE 2 DIABETES MELLITUS Cynthia Brown, MN, ANP, CDE.
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM (Part 1) Stan Schwartz MD, FACP, FACE.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Therapy of Type 2 Diabetes Mellitus: UPDATE
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stanley Schwartz,
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stanley Schwartz.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM (Part 2) Stan Schwartz MD, FACP, FACE.
Prevention Of Diabetes. Type 2 Diabetes: Hyperglycemia Insulin Resistance Relative Impairment of Insulin Secretion Pathogenesis: Poorly Understood Genetic.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.
© 2013 Eli Lilly and Company Managing insulin therapy in Insulin resistance Speaker name and affiliation Prescribing information is available on the last.
Management of Diabetes mellitus Prof. Dr. Surya Dharma, MS, Apt. Fakultas Farmasi Unand.
Part 4.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Physiology: Carbohydrate Metabolism. The pancreas the gland responsible. Insulin production and secretion. Insulin receptors. Glucose transporters. Insulin.
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics 5. Gut.
An American Epidemic. Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI ≥30 kg/m 2 ) Diabetes
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Efficacy of Immunotherapy in T1DM: Some Can Delay Decline in C-peptide
The β-Cell Centric Classification of DM
β-Cell Centric Classification of Diabetes:
Part 5 Stan Schwartz MD, FACP, FACE Private Practice, Ardmore
Treatment of Type 2 Diabetes: Pathophysiology Conclude: do so without Hypoglycemia or Visceral Fat Weight Gain 1.
Pushback What about ‘pure’ Insulin Resistance Syndromes?
Macrovascular Complications Microvascular Complications
WHAT ABOUT COMPLICATIONS OF DIABETES?
Presentation transcript:

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 4 Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program Cardiometabolic Diabetes Center and Affiliate,

Obesity, IRS, Type 2 Diabetes and Atherosclerotic Disease Obesity carries with it increase CV Risk Factors Risk factors for macrovascular disease accrue before the diagnosis of diabetes as > 50% of patients with newly diagnosed Type 2 diabetes have pre- existing cardiovascular disease. 2-4 fold > risk of ASVD in diabetic vs. normal patients Cardiovascular disease causes 80% of all diabetic mortality- 75% coronary, 25% cerebral vascular l Type 2 diabetes is associated with an increased risk of morbidity and mortality from cerebrovascular disease versus the general population, and > HgA1c, >risk

Outline Epidemiology and Economics of obesity/diabetes Perspectives on Obesity Consequences of Obesity, Prediabetes, Obesity Obesity/ Diabetes Risk Factors, Obesity/ Diabetes Onset can be Prevented or Delayed – Early Risk Identification and Intervention. Medical Benefits to Weight Loss Treatment-CDC’s diabetes prevention program and other Evidence-Based Interventions- –Basics, –Next Lecture in Series

Obesity leads to Prediabetes and Diabetes Mellitus-Type 2

Each unit increase in BMI (about kg) increases Type 2 diabetes risk by 12.1 percent % of diabetes risk in the U.S. is attributable to or associated with excess weight For every kilogram increase in weight over 10 years, Type 2 diabetes risk increases 4.5 % Ford et al. Amer J Epidemiol 146:214,1997

Relationship Between BMI and Risk of Type 2 Diabetes Mellitus Chan J et al. Diabetes Care 1994;17:961. Colditz G et al. Ann Intern Med 1995;122:481. Age-Adjusted Relative Risk Body Mass Index (kg/m 2 ) <23 24– –26.927–28.933– <22 23– –30.931– Men Women

Obesity, Insulin Resistance, Metabolic Syndrome and the Natural History of Type 2 Diabetes IR phenotype Atherosclerosis obesity hypertension  HDL,  TG, HYPERINSULINEMIA Endothelial dysfunction PCO,ED Envir.+ Other Disease Obesity (visceral) Poor Diet Inactivity Insulin Resistance Risk of Dev. Complications ETOH BP Smoking Eye Nerve Kidney  Beta Cell Secretion Genes Blindness Amputation CRF Disability MI CVA Amp Age Macrovascular Complications IGT – OMINOUS OCTET Type II DM 8 mechanisms of hyperglycemia Microvascular Complications DEATH pp>7.8mM

Genes that Cause or are Associated with Diabetes Insulin action Insulin receptor PPARG Obesity FTO MCR4 Insulin Secretion Neonatal KCNJ11/Kir6.2 ABCC8/Sur1 Insulin MODYHNF-1α,1β, 4 α Glucokinase PDX1/IPF1 Neurod1/Beta2 KLF11 CEL Mitochondrial diabetes Type 2 CDKAL1 TCF7L2 HHEX/IDE SLC30A8/ZNT8 WFS1 NOTCH2-ADAM30 Unknown IGFBP2 CDKN2A/B KIF11 JAZF1 CDC123-CAMK1D TSPAN8-LGR5 THADA ADAMTS9 NOTCH-ADAM30 PHENOTYPE- eg: age of presentation, IFG/ IGT/Both/ severity depends on number of which kind of genes a person inherits – GENOTYPE Modified from McCarthy, NEJM 363:24,2339.

Obesity, Insulin Resistance, Metabolic Syndrome and the Natural History of Type 2 Diabetes IR phenotype Atherosclerosis obesity hypertension  HDL,  TG, HYPERINSULINEMIA Endothelial dysfunction PCO,ED Envir.+ Other Disease Obesity (visceral) Poor Diet Inactivity Insulin Resistance Risk of Dev. Complications ETOH BP Smoking Eye Nerve Kidney  Beta Cell Secretion Genes Blindness Amputation CRF Disability MI CVA Amp Age Macrovascular Complications IGT – OMINOUS OCTET Type II DM 8 mechanisms of hyperglycemia Microvascular Complications DEATH pp>7.8

‘Ominous Octet: Pathophysiological Contributions to Hyperglycemia in Type 2 Diabetes 5.Gut carbohydrate absorption Peripheral glucose uptake Hepatic glucose production Pancreatic insulin secretion 2.Pancreatic glucagon secretion HYPERGLYCEMIA 6.Fat- increased lipolysis, inc FFA 7.Brain- Inc. Appetite Insulin Resistance, Decrease, GLP-1 8.Kidney- 3.Muscle 4.Liver ? ‘Nonet’- Gut Biome

Type 2 Diabetes: Two Principal Defects; Overview Reaven GM. Physiol Rev. 1995;75: Reaven GM. Diabetes/Metabol Rev. 1993;9(Suppl 1):5S-12S; Polonsky KS. Exp Clin Endocrinol Diabetes. 1999;107 Suppl 4:S124-S127. Insulin resistance- lipotoxicity  -cell dysfunction/ Failure; dec. mass ± Environment± IFGIGT Genes Type 2 diabetes Glucose Toxicity Glucose Toxicity hepatic peripheral Abn. first 1 st & 2nd Interactions will NOT occur if B-cells not genetically predisposed